| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
AChE-IN-23 targets acetylcholinesterase (AChE), a key enzyme in the cholinergic system that hydrolyzes the neurotransmitter acetylcholine. AChE is responsible for terminating synaptic transmission by breaking down acetylcholine into choline and acetate. By inhibiting AChE, AChE-IN-23 prevents the breakdown of acetylcholine, thereby increasing its concentration at the synapse. This mechanism is thought to enhance cholinergic neurotransmission and is a well-established therapeutic strategy for Alzheimer's disease and other dementias. The compound has an IC50 value of 48.3 μM against AChE.
|
|---|---|
| ln Vitro |
In vitro, AChE-IN-23 has been shown to be a potent inhibitor of acetylcholinesterase (AChE) with an IC50 value of 48.3 μM. Its inhibitory activity is measured in cell-free enzyme assays using purified AChE. The compound's ability to inhibit AChE is the basis for its potential therapeutic application in neurological diseases. By inhibiting AChE, the compound can increase acetylcholine levels, which may improve cognitive function. The compound's activity is dose-dependent, and its IC50 value is a measure of its potency.
|
| ln Vivo |
Specific in vivo activity data for AChE-IN-23 are not detailed in the available literature. However, as an AChE inhibitor, it is being developed for the treatment of neurological diseases, particularly Alzheimer's disease. Its potential in vivo effects would be to increase acetylcholine levels in the brain, thereby improving cognitive function. Further studies in animal models are needed to confirm its in vivo efficacy, pharmacokinetics, and safety. The compound is currently in the research phase.
|
| Enzyme Assay |
In vitro enzyme assays for AChE-IN-23 involve measuring the inhibition of acetylcholinesterase (AChE) activity. The enzyme is incubated with its substrate, acetylthiocholine, in a buffer solution. The hydrolysis of acetylthiocholine produces thiocholine, which reacts with 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) to form a yellow product that can be measured spectrophotometrically at 412 nm. Varying concentrations of AChE-IN-23 are added to the reaction mixture, and the enzyme activity is measured. The IC50 value, representing the concentration required to inhibit 50% of the enzyme activity, is calculated from the dose-response curve. The compound is typically dissolved in DMSO for stock solutions and diluted in the assay buffer.
|
| Cell Assay |
In vitro cell-based assays for AChE-IN-23 are not typically performed, as the compound's primary activity is as an enzyme inhibitor. However, its effects on neuronal cells could be studied by treating cells (e.g., neuronal cell lines or primary neurons) with the compound and measuring acetylcholine levels or assessing cholinergic signaling. The compound's ability to protect against neurotoxicity or improve cognitive function could also be evaluated in relevant cell-based models. The compound is typically dissolved in DMSO and diluted in cell culture medium for treatment.
|
| Animal Protocol |
Specific in vivo animal experiment protocols for AChE-IN-23 are not detailed in the available literature. However, as a potential treatment for Alzheimer's disease, it would likely be tested in animal models of the disease, such as transgenic mice expressing amyloid precursor protein (APP) or in models of cognitive impairment. The compound could be administered orally, intraperitoneally, or by other routes. Behavioral tests (e.g., Morris water maze, novel object recognition) would be used to assess cognitive function, and biochemical markers (e.g., acetylcholine levels, amyloid plaque load) would be measured in brain tissue.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of AChE-IN-23 have not been extensively characterized in the available literature. However, some physicochemical properties relevant to its PK can be inferred. The compound has a molecular weight of 267.20 g/mol and a formula of C11H20Cl2N2O. It is intended for research use only. The compound is typically stored as a powder at -20°C for up to 3 years or at 4°C for up to 2 years, and in solvent at -80°C for up to 6 months or at -20°C for up to 1 month.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for AChE-IN-23 are not provided in the available sources. As a research chemical, its safety profile in humans has not been established. The compound is classified as a research reagent and is not for therapeutic or veterinary use. Standard laboratory safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment. Its purity is typically high (e.g., 99.49%).
|
| References | |
| Additional Infomation |
AChE-IN-23 is a small molecule inhibitor of acetylcholinesterase (AChE) with an IC50 of 48.3 μM. It is also known as compound 3h and has the molecular formula C11H20Cl2N2O and a molecular weight of 267.20 g/mol. The compound is being investigated for its potential in treating neurological diseases, particularly Alzheimer's disease. By inhibiting AChE, the enzyme that breaks down the neurotransmitter acetylcholine, AChE-IN-23 aims to increase acetylcholine levels in the brain. The compound is intended for research use only and is not for human consumption.
|
| Molecular Formula |
C11H19N2O+
|
|---|---|
| Molecular Weight |
195.28136
|
| Exact Mass |
266.095
|
| CAS # |
6297-14-9
|
| PubChem CID |
2723878
|
| Appearance |
Off-white to gray solid powder
|
| Boiling Point |
325.3ºC at 760 mmHg
|
| Melting Point |
215-218ºC (dec.)(lit.)
|
| Flash Point |
150.5ºC
|
| LogP |
4.001
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
16
|
| Complexity |
159
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PLISWDVQSUTGTR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H18N2O.2ClH/c1-3-13(4-2)8-9-7-10(12)5-6-11(9)14;;/h5-7,14H,3-4,8,12H2,1-2H3;2*1H
|
| Chemical Name |
4-amino-2-(diethylaminomethyl)phenol;dihydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~374.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1209 mL | 25.6043 mL | 51.2085 mL | |
| 5 mM | 1.0242 mL | 5.1209 mL | 10.2417 mL | |
| 10 mM | 0.5121 mL | 2.5604 mL | 5.1209 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
